Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial

被引：0

作者：

Harbeck, Nadia ^{[1
,2
]}

Gluz, Oleg ^{[3
,4
,5
]}

Kuemmel, Sherko ^{[6
,7
]}

Christgen, Matthias ^{[8
]}

Braun, Michael ^{[9
]}

Aktas, Bahriye ^{[10
]}

Luedtke-Heckenkamp, Kerstin ^{[11
]}

Forstbauer, Helmut ^{[12
]}

Grischke, Eva-Maria ^{[13
]}

Schumacher, Claudia ^{[14
]}

Darsow, Maren ^{[15
]}

Krauss, Katja ^{[16
]}

Nuding, Benno ^{[17
]}

Thill, Marc ^{[18
]}

Potenberg, Jochem ^{[19
]}

Uleer, Christoph ^{[20
]}

Warm, Mathias ^{[21
]}

Fischer, Hans H. ^{[22
]}

Malter, Wolfram ^{[23
]}

Hauptmann, Michael ^{[24
]}

Kates, Ronald ^{[4
]}

Graeser, Monika ^{[3
,4
]}

Wuerstlein, Rachel ^{[1
,2
]}

Shak, Steve ^{[25
]}

Baehner, Rick ^{[25
]}

Kreipe, Hans ^{[8
]}

Nitz, Ulrike ^{[3
,4
]}

机构：

[1] LMU Univ Hosp, Dept OB&GYN, Breast Ctr, Munich, Germany

[2] LMU Univ Hosp, CCCLMU, Munich, Germany

[3] Johanniter Bethesda Moenchengladbach, Breast Ctr Niederrhein, Moenchengaldbach, Germany

[4] West German Study Grp, Moenchengaldbach, Germany

[5] Univ Cologne, Moenchengaldbach, Germany

[6] Clin Essen Mitte, Breast Unit, Essen, Germany

[7] West German Study Grp, Essen, Germany

[8] Med Coll Hannover, Inst Pathol, Hannover, Germany

[9] Breast Ctr, Clin Rotkreuz, Munich, Germany

[10] Univ Clin Leipzig, Womens Clin, Leipzig, Germany

[11] Niels Stensen Clin, Clin Oncol, Osnabruck, Germany

[12] Oncol Practice Network Troisdorf, Troisdorf, Germany

[13] Univ Clin Tubingen, Womens Clin, Tubingen, Germany

[14] St Elizabeth Hosp, Cologne, Germany

[15] Luisenhospital Duesseldorf, Practice Senol Oncol, Dusseldorf, Germany

[16] Univ Clin Aachen, Womens Clin, Aachen, Germany

[17] Ev Hosp Bergisch Gladbach, Bergisch Gladbach, Germany

[18] Agaples Markus Hosp, Breast Ctr, Frankfurt, Germany

[19] Ev Waldkrankenhaus Berlin, Berlin, Germany

[20] Gynecologists & Bahnhofspl, Hildesheim, Germany

[21] City Hosp Holweide, Breast Ctr, Cologne, Germany

[22] Evangel Kliniken, Gelsenkirchen, Germany

[23] Univ Clin Cologne, Womens Clin & Breast Ctr, Cologne, Germany

[24] Brandenburg Med Sch Theodor Fontane, Neuruppin, Germany

[25] Genom Hlth Inc, Redwood City, CA USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GS4-04

引用

页数：1

共 24 条

[1] Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2-translational results
Grote, I.
Bartels, S.
Kandt, L.
Bollmann, L.
Christgen, H.
Gronewold, M.
Gluz, O.
Nitz, U.
Kuemmel, S.
Braun, M.
Aktas, B.
Grischke, E-M.
Schumacher, C.
Luedtke-Heckenkamp, K.
Kates, R.
Wuerstlein, R.
Graeser, M.
Harbeck, N.
Christgen, M.
Kreipe, H.
ANNALS OF ONCOLOGY, 2020, 31 : S306 - S306
[2] Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2-chemotherapy trial.
Gluz, Oleg
Nitz, Ulrike
Christgen, Matthias
Braun, Michael
Luedtke-Heckenkamp, Kerstin
Darsow, Maren
Forstbauer, Helmut
Potenberg, Jochem
Uleer, Christoph
Grischke, Eva-Maria
Aktas, Bahriye
Schumacher, Claudia
zu Eulenburg, Christine
Jozwiak, Katarzyna
Kates, Ronald E.
Graeser, Monika
Wuerstlein, Rachel
Kreipe, Hans Heinrich
Kuemmel, Sherko
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2-early breast cancer: Primary results from the phase III NATALEE trial.
Stroyakovskiy, Daniil J.
Yardley, Denise A.
Huang, Chiun-Sheng
Fasching, Peter A.
Crown, John
Bardia, Aditya
Chia, Stephen
Im, Seock-Ah
Martin, Miguel
Loi, Sherene
Xu, Binghe
Hurvitz, Sara A.
Barrios, Carlos
Untch, Michael
Moroose, Rebecca L.
Visco, Fran
Fresco, Rodrigo
Taran, Tetiana
Hortobagyi, Gabriel N.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA500 - LBA500
[4] Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2-early breast cancer: Primary results from the phase III NATALEE trial.
Slamon, Dennis J.
Stroyakovskiy, Daniil
Yardley, Denise A.
Huang, Chiun-Sheng
Fasching, Peter A.
Crown, John
Bardia, Aditya
Chia, Stephen
Im, Seock-Ah
Martin, Miguel
Loi, Sherene
Xu, Binghe
Hurvitz, Sara A.
Barrios, Carlos
Untch, Michael
Moroose, Rebecca L.
Visco, Fran
Fresco, Rodrigo
Taran, Tetiana
Hortobagyi, Gabriel N.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[5] Quality of life from the Penelope-B study on high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib
Garcia-Saenz, J. A.
Marme, F.
Rugo, S.
Untch, M.
Bonnefoi, H.
Kim, S-B.
Bear, H. D.
McCarthy, N.
Gelmon, K.
Martin, M.
Kelly, C. M.
Reimer, T.
Toi, M.
Law, E. H.
Gnant, M.
Makris, A.
Seiler, S.
Burchardi, N.
Nekljudova, V.
Loibl, S.
ANNALS OF ONCOLOGY, 2021, 32 : S410 - S411
[6] Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes
Gluz, O.
Nitz, U.
Christgen, M.
Kates, R.
Clemens, M.
Nuding, B.
Shak, S.
Wuerstlein, R.
Kreipe, H.
Harbeck, N.
BREAST, 2017, 32 : S93 - S93
[7] Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
Paluch-Shimon, Shani
Neven, Patrick
Huober, Jens
Cicin, Irfan
Goetz, Matthew P. P.
Shimizu, Chikako
Huang, Chiun-Sheng
Lueck, Hans Joachim
Beith, Jane
Tokunaga, Eriko
Contreras, Jessica Reyes
de Sant'Ana, Rosane Oliveira
Wei, Ran
Shahir, Ashwin
Nabinger, Sarah C. C.
Forrester, Tammy
Johnston, Stephen R. D.
Harbeck, Nadia
monarchE Investigators
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[8] Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2-breast cancer with recurrence score </25 randomized to endocrine therapy plus /- chemotherapy: results from SWOG S1007 (RxPONDER)
Spring, Laura M.
Barlow, William E.
Bardia, Aditya
Sharma, Priyanka
Pusztai, Lajos
Hortobagyi, Gabriel N.
Kalinsky, Kevin
CANCER RESEARCH, 2023, 83 (05)
[9] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Tolaney, Sara M.
Fallowfield, Lesley
Kaufman, Peter A.
Ciruelos, Eva M.
Gainford, Mary Corona
Lu, Yi
Hurt, Karla
Wasserstrom, Heather Ann
Chen, Yanyun
Goel, Shom
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Hamilton, Erika P.
Kim, Jee Hyun
Eigeliene, Natalja
Mavroudis, Dimitrios
Median, Dragos Mircea
Marconato, Heloisa
Shevnia, Serhii
Ozyilkan, Ozgur
Puig, Juan Manuel
Shannon, Catherine M.
Munoz, Maria
San Antonio, Belen
Wei, Ran
O'Shaughnessy, Joyce
Johnston, Stephen R. D.
Guarneri, Valentina
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 →

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score &lt;26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial